Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03277352 · OUTCOME

Phase 1 & Phase 2: Progression-free Survival Based on RECIST v1.1 and mRECIST

INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies · Source last updated 2021-07-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Assessed every 9 weeks for 12 months, then every 12 weeks, up to 18 months

What was measured

Defined as the time from the start of combination therapy until the earliest date of disease progression or death due to any cause.

Analysis population: The FAS includes all participants enrolled in the study who received at least 1 dose of INCAGN01876, pembrolizumab, or epacadostat.

Groups in this outcome

INCAGN01876 + Pembrolizumab + Epacadostat

INCAGN01876 in combination with pembrolizumab and epacadostat

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
INCAGN01876 + Pembrolizumab + Epacadostat10

Reported measurements

mRECIST
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
INCAGN01876 + Pembrolizumab + Epacadostat17.36Not reported2.05NAThe number of responders is not enough to estimate a standard error for the confidence interval.
RECIST
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
INCAGN01876 + Pembrolizumab + Epacadostat4.20Not reported0.73NAThe number of responders is not enough to estimate a standard error for the confidence interval.
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        The number of responders is not enough to estimate a standard error for the confidence interval.
        group Id
        OG000
        lower Limit
        2.05
        upper Limit
        NA
        value
        17.36
    title
    mRECIST
  2. categories
    1. measurements
      1. comment
        The number of responders is not enough to estimate a standard error for the confidence interval.
        group Id
        OG000
        lower Limit
        0.73
        upper Limit
        NA
        value
        4.20
    title
    RECIST
denoms
  1. counts
    1. group Id
      OG000
      value
      10
    units
    Participants
description
Defined as the time from the start of combination therapy until the earliest date of disease progression or death due to any cause.
dispersion Type
95% Confidence Interval
groups
  1. description
    INCAGN01876 in combination with pembrolizumab and epacadostat
    id
    OG000
    title
    INCAGN01876 + Pembrolizumab + Epacadostat
param Type
MEDIAN
population Description
The FAS includes all participants enrolled in the study who received at least 1 dose of INCAGN01876, pembrolizumab, or epacadostat.
reporting Status
POSTED
time Frame
Assessed every 9 weeks for 12 months, then every 12 weeks, up to 18 months
title
Phase 1 & Phase 2: Progression-free Survival Based on RECIST v1.1 and mRECIST
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice